osimertinib: Clinical Trials

159 trials of osimertinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

45 recruiting, 33 completed, 32 active not recruiting, 25 unknown. 159 Phase 2, 32 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2159Recruiting 45, Completed 33, Active not recruiting 32, Unknown 25, Not yet recruiting 17, Terminated 7
Phase 132Recruiting 12, Completed 8, Active not recruiting 5, Not yet recruiting 3, Terminated 2, Unknown 2
Phase 36Recruiting 3, Active not recruiting 1, Completed 1, Not yet recruiting 1

Follow osimertinib: new trials by email Literature Review of osimertinib trials Research Report on osimertinib

Trials (filtered) newest first · largest first

All 159 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMisty Shields162027-01-012026-10-15
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
Capivasertib in combination with Osimertinib - Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Phase 1 / Phase 2Not yet recruitingShanxi Province Cancer Hospital532026-12-082026-11-19
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Phase 2RecruitingNYU Langone Health602026-10-012026-10-15
A Phase 2 Study of ABSK043 Combined With Osimertinib
ABSK043 in combination with Osimertinib - Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Phase 2Not yet recruitingAbbisko Therapeutics Co, Ltd722026-08-312026-07-17
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
BL-B01D1, Osimertinib, Carboplatin - Non-small Cell Lung Cancer
Phase 2 / Phase 3RecruitingSichuan Baili Pharmaceutical Co., Ltd.902026-07-242026-08-03
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
SKB571 for injection, Osimertinib, Furmonertinib - Non-Small Cell Lung Cancer
Phase 2RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1502026-07-152026-09-02
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
AK146D1 for injection, AK112 Injection, Platinum chemotherapy - Advanced Non Small Cell Lung Cancer (NSCLC)
Phase 2RecruitingAkeso3482026-07-102026-07-14
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
ALK202 for injection, Osimertinib Mesylate Tablets, Ivonescimab Injection - NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 2Not yet recruitingShanghai Allink Biotherapeutics Co., Ltd.2522026-06-302026-05-22
Boosting Osimertinib Blood Brain Barrier Penetration
Osimertinib & febuxostat - Non-Small Cell Lung Cancer
Phase 2RecruitingMaastricht University Medical Center72026-06-012026-06-05
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation
Phase 1 / Phase 2Not yet recruitingBeijing Pearl Biotechnology Limited Liability Company2532026-06-012025-12-16
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor
Phase 1 / Phase 2Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.2822026-06-012026-05-28
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Ivonescimab, Dato-DXd, Osimertinib - Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center662026-04-092026-07-13
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Osimertinib - Lung Cancer
Phase 2RecruitingAstraZeneca602026-04-012026-10-28
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Sacituzumab Tirumotecan, Osimertinib - Non-Small Cell Lung Cancer
Phase 2RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.302026-03-302026-08-20
Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
Osimertinib, Stereotactic Radiosurgery - Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Phase 2RecruitingCho Ray Hospital412026-02-272026-11-12
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Non-Small Cell Carcinoma
Phase 2RecruitingJonsson Comprehensive Cancer Center602026-02-192026-04-20
Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Local ablative therapy, Osimertinib alone - Lung Cancer (NSCLC)
Phase 2RecruitingChinese University of Hong Kong642026-02-112026-02-12
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O, Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer - Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital742026-01-012026-04-01
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Osimertinib + Sacituzumab Tirumotecan, Osimertinib - Non Small Cell Lung Cancer
Phase 2RecruitingGuangdong Association of Clinical Trials1202025-12-152026-05-26
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Telisotuzumab Adizutecan, Standard of Care, Osimertinib - Non-Small Cell Lung Cancer, c-MET
Phase 2 / Phase 3RecruitingAbbVie4902025-12-102026-10-05

Showing 20 of 159. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (111)  ·  Lung Neoplasms (35)  ·  Brain Neoplasms (7)  ·  Neoplasm Metastasis (6)  ·  Neoplasms (5)  ·  Adenocarcinoma of Lung (3)  ·  Breast Neoplasms (3)  ·  Carcinoma, Squamous Cell (3)  ·  Colorectal Neoplasms (3)  ·  Meningeal Carcinomatosis (3)  ·  Ovarian Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Bronchial Neoplasms (2)  ·  Carcinoma (2)  ·  Hematologic Neoplasms (2)

Sponsors

AstraZeneca (14)  ·  National Cancer Institute (NCI) (6)  ·  Tianjin Medical University Cancer Institute and Hospital (5)  ·  Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Samsung Medical Center (4)  ·  Sichuan Baili Pharmaceutical Co., Ltd. (4)  ·  Dana-Farber Cancer Institute (3)  ·  Guangdong Association of Clinical Trials (3)  ·  Jonsson Comprehensive Cancer Center (3)  ·  Shanghai JMT-Bio Inc. (3)  ·  Sun Yat-sen University (3)  ·  AbbVie (2)  ·  ETOP IBCSG Partners Foundation (2)  ·  Hunan Province Tumor Hospital (2)

Countries

China (61)  ·  United States (55)  ·  South Korea (29)  ·  Spain (19)  ·  Taiwan (15)  ·  Italy (14)  ·  Singapore (11)  ·  France (10)  ·  Netherlands (10)  ·  Germany (8)  ·  Australia (7)  ·  Canada (7)  ·  Japan (7)  ·  Belgium (6)  ·  Hong Kong (6)

Top investigators

Helena Yu, MD (3)  ·  Li Zhang (2)  ·  Liu Anwen, Phd (2)  ·  Nir Peled, MD PhD FCCP (2)  ·  Sarah B Goldberg (2)  ·  Alessandro Morabito, MD (1)  ·  Amanda Tufman, Prof. Dr. (1)  ·  Anjali Rohatgi, M.D., Ph.D. (1)  ·  Arya Amini (1)  ·  Athanasios Kotsakis, PhD (1)  ·  Azam Ghafoor, M.D. (1)  ·  Caicun Zhou (1)  ·  Caicun Zhou, Doctorate (1)

Results publications

PMID 25175099, PMID 27959700, PMID 29151359, PMID 29293889, PMID 30512189, PMID 31085043, PMID 31345012, PMID 32027845, PMID 40311309, PMID 41534788, PMID 17374728, PMID 17894407, PMID 20595147, PMID 21784628, PMID 22487432, PMID 24644001, PMID 24893891, PMID 25695221, PMID 25923549, PMID 26181354, PMID 26473643, PMID 26494259, PMID 26586415, PMID 27354477, PMID 27435396, PMID 27751847, PMID 28105214, PMID 28408243, PMID 28577957, PMID 28627678, PMID 28751247, PMID 28765329, PMID 28841389, PMID 28857200, PMID 28881293, PMID 29290249, PMID 29307353, PMID 29363250, PMID 29438373, PMID 29700687, PMID 29782558, PMID 29858027, PMID 30059262, PMID 30073261, PMID 30975627, PMID 31108248, PMID 31648999, PMID 31751012, PMID 31825714, PMID 32200138

NIH funding

2023 (4), 2015 (3), 2017 (3), U10CA180820 (3), 2014 (2), 2018 (2), 2025 (2), 2016 (1), 2019 (1), P30CA033572 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186689 (1), UM1CA186712 (1)